<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Head and Neck Tumors</journal-id><journal-title-group><journal-title xml:lang="en">Head and Neck Tumors</journal-title><trans-title-group xml:lang="ru"><trans-title>Опухоли головы и шеи</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2222-1468</issn><issn publication-format="electronic">2411-4634</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">719</article-id><article-id pub-id-type="doi">10.17650/2222-1468-2021-11-4-73-80</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL REPORT</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Characteristics of composition a lymphoid infiltrate in the tongue squamous cell carcinoma</article-title><trans-title-group xml:lang="ru"><trans-title>Особенности состава лимфоидного инфильтрата при плоскоклеточном раке языка</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5252-0436</contrib-id><name-alternatives><name xml:lang="en"><surname>Zibirov</surname><given-names>R. F.</given-names></name><name xml:lang="ru"><surname>Зибиров</surname><given-names>Р. Ф.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Ruslan Fiaritovich Zibirov</p><p>4 Koroleva St., Obninsk 249036</p></bio><bio xml:lang="ru"><p>Руслан Фяритович Зибиров</p><p>249036 Обнинск, ул. Королева, 4</p></bio><email>patologr@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2168-2616</contrib-id><name-alternatives><name xml:lang="en"><surname>Mozerov</surname><given-names>S. A.</given-names></name><name xml:lang="ru"><surname>Мозеров</surname><given-names>С. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>4 Koroleva St., Obninsk 249036</p></bio><bio xml:lang="ru"><p>249036 Обнинск, ул. Королева, 4</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0857-321X</contrib-id><name-alternatives><name xml:lang="en"><surname>Polkin</surname><given-names>V. V.</given-names></name><name xml:lang="ru"><surname>Полькин</surname><given-names>В. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>4 Koroleva St., Obninsk 249036</p></bio><bio xml:lang="ru"><p>249036 Обнинск, ул. Королева, 4</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9756-6275</contrib-id><name-alternatives><name xml:lang="en"><surname>Sevrukov</surname><given-names>F. E.</given-names></name><name xml:lang="ru"><surname>Севрюков</surname><given-names>Ф. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>4 Koroleva St., Obninsk 249036</p></bio><bio xml:lang="ru"><p>249036 Обнинск, ул. Королева, 4</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9457-3034</contrib-id><name-alternatives><name xml:lang="en"><surname>Medvedev</surname><given-names>V. S.</given-names></name><name xml:lang="ru"><surname>Медведев</surname><given-names>В. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>4 Koroleva St., Obninsk 249036</p></bio><bio xml:lang="ru"><p>249036 Обнинск, ул. Королева, 4</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Raykova</surname><given-names>A. P.</given-names></name><name xml:lang="ru"><surname>Райкова</surname><given-names>А. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>7 / 9 Universitetskaya Emb., Saint Petersburg 199034</p></bio><bio xml:lang="ru"><p>199034 Санкт-Петербург, Университетская набережная, 7–9</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Riss</surname><given-names>M. E.</given-names></name><name xml:lang="ru"><surname>Рисс</surname><given-names>М. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>41 Bolshaya St. Petersburg St., Veliky Novgorod 173003</p></bio><bio xml:lang="ru"><p>173003 Великий Новгород, ул. Большая Санкт-Петербургская, 41</p></bio><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">A. Tsyb Medical Radiological Research Centre – branch of the National Medical Research Centre of Radiology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">Медицинский радиологический научный центр им. А. Ф. Цыба – филиал ФГБУ «Национальный медицинский исследовательский центр» радиологии Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Saint Petersburg University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Санкт-Петербургский государственный университет»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Yaroslav-the-Wise Novgorod State University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Новгородский государственный университет им. Ярослава Мудрого»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-12-14" publication-format="electronic"><day>14</day><month>12</month><year>2021</year></pub-date><volume>11</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>73</fpage><lpage>80</lpage><history><date date-type="received" iso-8601-date="2022-02-14"><day>14</day><month>02</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-02-14"><day>14</day><month>02</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Zibirov R.F., Mozerov S.A., Polkin V.V., Sevrukov F.E., Medvedev V.S., Raykova A.P., Riss M.E.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, Зибиров Р.Ф., Мозеров С.А., Полькин В.В., Севрюков Ф.Е., Медведев В.С., Райкова А.П., Рисс М.Е.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Zibirov R.F., Mozerov S.A., Polkin V.V., Sevrukov F.E., Medvedev V.S., Raykova A.P., Riss M.E.</copyright-holder><copyright-holder xml:lang="ru">Зибиров Р.Ф., Мозеров С.А., Полькин В.В., Севрюков Ф.Е., Медведев В.С., Райкова А.П., Рисс М.Е.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ogsh.abvpress.ru/jour/article/view/719">https://ogsh.abvpress.ru/jour/article/view/719</self-uri><abstract xml:lang="en"><p><bold>Introduction</bold>. Squamous cell carcinoma of the tongue is the most common oral cancer. The tumor microenvironment has a significant impact on tumor progression; therefore, better understanding of its characteristics is crucial for the treatment strategy, since in some cases it modifies the tumor microenvironment resulting in tumor resistance to therapy.</p><p><bold>Study objective</bold> – to compare the number of CD8+Т-lymphocytes, CD57+NK-cells, and CD20+B-lymphocytes in the microenvironment of tongue squamous cell carcinoma in patients receiving and not receiving neoadjuvant chemoradiotherapy.</p><p><bold>Materials and methods</bold>. We performed immunohistochemical examination of specimens from 67 patients with tongue squamous cell carcinoma who did not receive neoadjuvant chemoradiotherapy. Eleven patients were diagnosed with well differentiated tumors (G1); 21 patients had moderately differentiated tumors (G2); and 35 patients had poorly differentiated tumors (G3). T1 tumors were observed in 11 individuals, T2 tumors – in 26 individuals, T3 tumors – in 26 individuals, and T4 tumors – in 4 individuals. We also examined 30 patients who had undergone neoadjuvant chemoradiotherapy, including external beam radiotherapy (total dose of 60 Gy) and a cycle of polychemotherapy (cisplatin and 5‑fluorouracil). Of them, 6 patients had T1 tumors, 17 patients – T2 tumors, 5 patients – T3 tumors, and 2 patients – T4 tumors. We measured the areas occupied by CD8+T-lymphocytes, CD20+B-lymphocytes, and CD57+NK-cells in the hot spots in the tumor microenvironment.</p><p><bold>Results</bold>. The number of CD8+T-lymphocytes in the tumor microenvironment was higher in patients after neoadjuvant chemoradiotherapy than in those who did not receive it (р = 0.000), whereas the number of CD20+B-lymphocytes was lower after neoadjuvant chemoradiotherapy. The area occupied by CD57+NK-cells in the hot spots of the tumor microenvironment did not differ significantly before and after therapy (p &gt;0.05).</p><p><bold>Conclusion</bold>. Thus, neoadjuvant chemoradiotherapy in patients with tongue squamous cell carcinoma caused an increase in the number of CD8+T-lymphocytes, a decrease in the number of CD20+B-lymphocytes in the tumor microenvironment, and had no effect on the population of CD57+NK-cells.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение</bold>. Плоскоклеточный рак языка – наиболее частая локализация рака ротовой полости. Опухолевое клеточное микроокружение имеет большое влияние на прогрессирование опухоли. Понимание особенностей состава опухолевого микроокружения является основой лечебной тактики, так как в ряде случаев она модифицирует опухолевое микроокружение, что приводит к резистентности опухоли к применяемой терапии.</p><p><bold>Цель исследования</bold> – сравнить количество CD8+Т-лимфоцитов, CD57+NK-клеток (natural killer cells) и CD20+B-лимфоцитов в клеточном опухолевом микроокружении при плоскоклеточном раке языка в группах без неоадъювантной химиолучевой терапии и с применением данной терапии.</p><p><bold>Материалы и методы</bold>. Проведено иммуногистохимическое исследование образцов ткани от 67 пациентов с плоскоклеточным раком языка, не получавших неоадъювантную химиолучевую терапию. У 11 больных выявлены высокодифференцированные опухоли (G1), у 21 – умеренно дифференцированные (G2), у 35 – низкодифференцированные (G3). Заболевание стадии Т1 наблюдалось в 11 случаях, стадии Т2 – в 26, стадии Т3 – в 26, стадии Т4 – в 4 случаях. Также исследовали данные 30 пациентов, которым проведена неоадъювантная химиолучевая терапия, включавшая дистанционную гамма-терапию (суммарная очаговая доза 60 Гр) и цикл полихимиотерапии (цисплатин и 5‑фторурацил). У 6 из них была опухоль стадии T1, у 17 – стадии T2, y 5 – стадии T3, y 2 – стадии T4. Изучалась площадь, которую занимали CD8+-T-лимфоциты, CD20+-B-лимфоциты и CD57+-NK-клетки в "горячих точках" клеточного опухолевого микроокружения.</p><p><bold>Результаты</bold>. Количество CD8+T-лимфоцитов в клеточном опухолевом микроокружении после неоадъювантной ХЛТ было больше, чем в случаях, когда она не проводилась (р = 0,000), а CD20+-B-лимфоцитов – меньше (р = 0,004). Площадь, занимаемая CD57+-NK-клетами в "горячих точках" микроокружения опухоли, до и после терапии значимо не различалась (р &gt;0,05).</p><p><bold>Заключение</bold>. Таким образом, неоадъювантная химиолучевая терапия при плоскоклеточном раке языка приводит к увеличению количества CD8+-T-лимфоцитов, уменьшению количества CD20+-В-лимфоцитов в микроокружении опухоли и не оказывает влияния на популяцию CD57+-NK-клеток.</p></trans-abstract><kwd-group xml:lang="en"><kwd>squamous cell carcinoma of the tongue</kwd><kwd>neoadjuvant chemoradiotherapy</kwd><kwd>CD8+T-lymphocytes</kwd><kwd>CD57+NK-cells</kwd><kwd>CD20+B-lymphocytes</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>плоскоклеточный рак языка</kwd><kwd>неоадъювантная химиолучевая терапия</kwd><kwd>CD8+-T-лимфоциты</kwd><kwd>CD57+NK-клетки</kwd><kwd>CD20+-В-лимфоциты</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Torre L.A., Bray F., Siegel R.L. et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65(2):87–108. DOI: 10.3322/caac.21262.</mixed-citation></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Malignant neoplasms in Russia in 2017 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinsky, G.V. Petrova. M.: P.A. Hertsen Moscow State Medical Research Institute – branch of “NMIC of Radiology”, Ministry of Health of Russia, 2018. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>Bello I.O., Soini Y., Salo T. Prognostic evaluation of oral tongue cancer: means, markers and perspectives (I). Oral Oncol 2010;46(9):630–5. DOI: 10.1016/j.oraloncology.2010.06.006.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Koontongkaew S. The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas. J Cancer 2013;4(1):66–83.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Balermpas P., Michel Y., Wagenblast J. et al. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer 2014;110(2):501–9. DOI: 10.1038/bjc.2013.640.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Motohashi S., Nakayama T. Clinical applications of natural killer T cell-based immunotherapy for cancer. Cancer Sci 2008;99(4):638–45. DOI: 10.1111/j.1349-7006.2008.00730.x.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Schmidt M., Hellwig B., Hammad S. et al. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 2012;18(9):2695–703. DOI: 10.1158/1078-0432.CCR-11-2210.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Miyauchi S., Kim S.S., Pang J. et al. Immune modulation of head and neck squamous cell carcinoma and the tumor microenvironment by conventional therapeutics. Clin Cancer Res 2019;25(14):421123. DOI: 10.1158/1078-0432.CCR-18-0871.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Vincent J., Mignot G., Chalmin F. et al. 5-Fluorouracil selectively kills tumorassociated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010;70(8):3052–61. DOI: 10.1158/0008-5472.CAN-09-3690.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Mondini M., Nizard M., Tran T. et al. Synergy of radiotherapy and a cancer vaccine for the treatment of HPV-Associated head and neck cancer. Mol Cancer Ther 2015;14(6):1336–45. DOI: 10.1158/1535-7163.MCT-14-1015.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Yoon M.S., Pham C.T., Phan M.T. et al. Irradiation of breast cancer cells enhances CXCL16 ligand expression and induces the migration of natural killer cells expressing the CXCR6 receptor. Cytotherapy 2016;18(12):1532–42. DOI: 10.1016/j.jcyt.2016.08.006.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Wirsdörfer F., Cappuccini F., Niazman M. et al. Thorax irradiation triggers a local and systemic accumulation of immunosuppressive CD4+ FoxP3+ regulatory T cells. Radiat Oncol 2014;9:98. DOI: 10.1186/1748-717X-9-98.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Kelly R.J., Zaidi A.H., Smith M.A. et al. The Dynamic and transient immune micro-environment in locally advanced esophageal adenocarcinoma post chemoradiation. Ann Surg 2018;268(6):992–9. DOI: 10.1097/SLA.0000000000002410.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Lim Y.J., Koh J., Kim S. et al. Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+tumor-infiltrating lymphocytes identified patients with poor prognosis in rectal cancer: a matched comparison analysis. Int J Radiat Oncol Biol Phys 2017;99(5):1216–24. DOI: 10.1016/j.ijrobp.2017.07.004.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Ogura A., Akiyoshi T., Yamamoto N. et al. Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer. Eur J Cancer 2018;91:11–20. DOI: 10.1016/j.ejca.2017.12.005.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Park S., Joung J.G., Min Y.W. et al. Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma. J Immunother Cancer 2019;7(1):128. DOI: 10.1186/s40425-019-0609-x.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Zhou S., Yang H., Zhang J. et al. Changes in indoleamine 2,3-dioxygenase 1 expression and CD8+ tumor-Infiltrating lymphocytes after neoadjuvant chemoradiation therapy and prognostic significance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2020;108(1):286–94. DOI: 10.1016/j.ijrobp.2020.01.020.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Yoneda K., Kuwata T., Mori M. et al. Alteration in tumor immune microenvironment after chemoradiotherapy for locally advanced non-small cell lung cancer. J Clin Oncol 2019;37(15):8530. DOI: 10.1200/JCO.2019.37.15.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Berntsson J., Nodin B., Eberhard J. et al. Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer. Int J Cancer 2016;139(5):1129–39. DOI: 10.1002/ijc.30138.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Fu S.L., Pierre J., Smith-Norowitz T.A. et al. Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells. Clin Exp Immunol 2008;153(3):401–9. DOI: 10.1111/j.1365-2249.2008.03726.x.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Agarwal R., Chaudhary M., Bohra S. et al. Evaluation of natural killer cell (CD57) as a prognostic marker in oral squamous cell carcinoma: An immunohistochemistry study. J Oral Maxillofac Pathol 2016;20(2):173–7. DOI: 10.4103/0973-029X.185933.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Fang J., Li X., Ma D. et al. Prognostic significance of tumor infiltrating immune cells in oral squamous cell carcinoma. BMC Cancer 2017;17(1):375. DOI: 10.1186/s12885-017-3317-2.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Zancope E., Costa N.L., JunqueiraKipnis A.P. et al. Differential infiltration of CD8+ and NK cells in lip and oral cavity squamous cell carcinoma. J Oral Pathol Med 2010;39(2):162–7. DOI: 10.1111/j.1600-0714.2009.00792.x.</mixed-citation></ref></ref-list></back></article>
